Kornimate/medical-research-clean huggingface dataset:
attachment-based family therapy for adolescents with binge eating

Conditions: Bulimia Nervosa; Binge-Eating Disorder; Other Specified Feeding or Eating Disorder

Summary: the purpose of this study is to examine whether attachment-based family therapy (abft), a well-validated treatment for adolescents with depression and suicidality, is feasible and acceptable for adolescents with binge eating and their families.

this study involves a phone screen and baseline assessment to determine eligibility. participants who are eligible for the study will receive 16 weeks of abft treatment. the treatment primarily focuses on improving communication and relationships within the family, and will also address disordered eating behaviors (e.g., binge eating, laxative use, self-induced vomiting). all participants enrolled in the study will receive the same treatment. participants will also complete research assessments throughout treatment, at the end of treatment, and 3-months after the end of treatment. research assessments include a battery of questionnaires and interviews.

Eligibility criteria:
inclusion criteria: * speak, write, and understand english * age 12-22 years old * have a diagnosis of dsm-5 an, bn, bed, or osfed * medically stable for outpatient treatment * must have a parent, guardian, or primary caregiver who is willing to participate in the study and treatment exclusion criteria: * acute suicide risk * no parent or guardian agreement to participate * are currently receiving psychological treatment for an eating disorder * are currently receiving weight loss treatment * co-morbid clinically significant psychological disorder that would require attention beyond the study treatment (e.g., psychotic disorder, substance dependence) * diagnosis of intellectual disability
smart scales with bioimpedance analysis for treatment guidance in decompensated heart failure

Conditions: Heart Failure; With Decompensation

Summary: in this trial the measurement of whole body water will be compared to the standard method of measuring the body weight as treatment guidance in patients with decompensated heart failure. the seca mbca 515 \[medical body composition analyser\] will be used to quantify the whole body water by using bioelectrical impedance analysis.

investigators will include 153 participants hospitalized in the university hospital in basel. daily measurements of whole body water and body weight will be performed in each person until diuretic treatment is stopped or the patient is discharged from hospital, respectively. primary endpoint is the correlation between reduction of whole body water (in kg) and reduction of body weight (in kg) in patients with decompensated heart failure receiving forced diuretic treatment (max. deviation +/- 1kg).

Eligibility criteria:
inclusion criteria: * able to give informed consent * hospitalization because of decompensated heart failure treated with forced diuresis * able to stand on the scale without help from others and able to hold handrails with both hands exclusion criteria: * refusal to share personal data * implantable electronic device (e.g. pacemaker, etc.) * condition that does not allow skin contact of soles of feet and scale or hands with handrail (leg prosthesis, wounds, bandage, etc.)

Keywords: heart failure cardial decompensation smart scale bioimpedance analysis whole body water
the purpose of this registry study is to learn more about metabolic health: approximately 15,000 participants who are overweight or have obesity with or without metabolic diseases are expected to participate in this registry study.

Conditions: Metabolic Health

Summary: the purpose of this registry study is to learn more about metabolic health. the information gathered will be used to support research on the natural history of obesity and weight related diseases, their treatments, and how it affects overall health. approximately 15,000 participants who are overweight or have obesity with or without metabolic diseases are expected to participate in this registry study.

the vitality registry is a research study to collect healthcare information on people with conditions related to their weight which is stored in a database. participants, along with their doctor, provide the health information that makes up this database. participants will not be asked to take any special treatments or tests as part of the study. participants will be asked to complete questionnaires 2 times a year for up to 10 years, and the doctor will be asked to enter certain available information from office visits 1 time per year for up to 10 years regarding health, treatments, and symptoms related to the participants metabolic health. the information that will be collected for this study will include demographics (for example, age, gender, race, employment, etc.), medical history (including all prior and current treatments), social history, details about your metabolic health, how metabolic health impacts daily life, mental health, and satisfaction with treatment.

Eligibility criteria:
inclusion criteria: * at least 18 years of age (or age of majority) * willing to provide consent to participate exclusion criteria: -
comparison of curative effect between new tension band and patellar tension reduction band in the treatment of lower pole fractures of patella

Conditions: Follow-up Time, Postoperative Knee Joint Score, Postoperative X-ray, Follow-up Postural Image Data

Summary: research purposes: analyze the curative effect of the new tension band system composed of φ3.0mm hollow nails, titanium cables and new gaskets and the patellar tension reduction band in the treatment of lower pole fractures of the patella. research method: a retrospective study of 41 cases of comminuted fractures of the lower pole of the patella treated with a new tension band system composed of φ3.0mm hollow nails, titanium cables and new spacers from march 2012 to july 2017, including 19 males and 22 females , the average age is 56.7 years (22 to 79 years), 24 cases of ao/ota a1 type, and 17 cases of c1.3 type. during the same period, 22 cases of comminuted fractures of the lower pole of the patella were treated with a patella tension band, including 8 males and 14 females, with an average age of 57.4 years (32 to 84 years), 17 cases of ao/ota type a1, and 5 cases of type c1.3. the injury mechanism is all slipping and kneeling injuries.

research purposes: analyze the curative effect of the new tension band system composed of φ3.0mm hollow nails, titanium cables and new gaskets and the patellar tension reduction band in the treatment of lower pole fractures of the patella. research method: a retrospective study of 41 cases of comminuted fractures of the lower pole of the patella treated with a new tension band system composed of φ3.0mm hollow nails, titanium cables and new spacers from march 2012 to july 2017, including 19 males and 22 females , the average age is 56.7 years (22 to 79 years), 24 cases of ao/ota a1 type, and 17 cases of c1.3 type. during the same period, 22 cases of comminuted fractures of the lower pole of the patella were treated with a patella tension band, including 8 males and 14 females, with an average age of 57.4 years (32 to 84 years), 17 cases of ao/ota type a1, and 5 cases of type c1.3. the injury mechanism is all slipping and kneeling injuries.

Eligibility criteria:
inclusion criteria:patients with comminuted fractures of the lower pole of the patella: ao/ota type a1 and c1.3 type - exclusion criteria:1. except for other types of patella fractures 2. except for open patella fractures 3. excluding patients with other fractures and injuries 4. exclude patients who cannot cooperate with functional exercises -
evaluating effectiveness and long term safety of damoctocog alfa pegol in patients, who have been diagnosed with hemophilia a

Conditions: Hemophilia A

Summary: the aim of the hem-powr study is to understand better how damoctocog alfa pegol (jivi) is used to treat people with hemophilia a in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of hemophilia a. * patients previously treated for hemophilia a. * patients without previous history of inhibitors or patients with previous history of inhibitors on standard prophylaxis therapy for at least 1 year prior to study entry. * no current evidence of fviii inhibitor or clinical suspicion of fviii inhibitor. * initiation of or currently on damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis). * signed informed consent/assent. exclusion criteria: * concurrent participation in an investigational program with interventions outside of routine clinical practice. * diagnosis of any other bleeding/coagulation disorder other than hemophilia a. * contra-indications according to the local marketing authorization. * patient on immune tolerance induction (iti) treatment at the time of enrollment.
to study the effects of baby drink on vision care

Conditions: Myopia

Summary: baby drink is a formula based on lutein, mixed with blueberry fermented liquid, vitamins and minerals. lutein is an effective antioxidant to prevent retinal damage caused by blue light, but it cannot be produced in the human body and depends on dietary intake. blueberry fermented liquid is rich in polyphenolic compounds with excellent antioxidant capacity and the potential to reduce oxidative damage to eye cells caused by ultraviolet rays. with the prevalence of 3c products, myopia patients are increasing year by year in various regions, and suffer from eye diseases or vision loss with different degrees of complications. in this study, the subjects were provided with baby drink and tracked the degree of visual fatigue by regular questionnaires, and measured for visual acuity, axial length and diopter. the aim of this study is to investigate the protection of baby drink on visual acuity and visual fatigue.

1. visual acuity measurement: snellen's chart was used to measure visual acuity. 2. refractive examination: measure binocular refraction with open field computer refractor (shin-nippon nvision k5001 wide view). 3. measuring the axial length of the eye: use the multifunctional optical eyeball length measuring instrument (lenstar) to measure the distance from the instrument to the optical paths such as the cornea, lens, and retina, and then convert to the axial length of the eye. 4. corneal radian measurement: use a keratometer (bausch \& lomb keratometer) to measure the corneal radian and curvature, and estimate the degree of corneal astigmatism. 5. visual fatigue questionnaire survey: a visual fatigue scale questionnaire was designed using ocular surface disease index (osdi) and computer vision syndrome (cvs).

Eligibility criteria:
inclusion criteria: 1. adults aged 20 or over 2. willing to participate in this study and sign the subject's consent form 3. myopia less than 700 degrees exclusion criteria: 1. have consumed related eye care products in past 3 months 2. those who have eye infection in the past 3 months 3. people who have been diagnosed with any eye diseases in past 3 months 4. those who are allergic to cicadae
bold functional magnetic resonance imaging (fmri) and cerebral blood flow measurements as biomarkers for cognition enhancing drugs (3134-006)

Conditions: Dementia

Summary: this study will evaluate functional magnetic resonance imaging (fmri) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.


Eligibility criteria:
inclusion criteria: * subject is a nonsmoker * subject is in generally good health * subject has normal (or corrected to normal) vision and hearing * subject is right-handed exclusion criteria: * subject has a history of any illness that would make participation unsafe or would make the study results difficult to interpret * subject has a history of stroke, seizures, or major neurological disorders * subject has a history of cancer * subject has permanent cosmetic or metallic implants that would interfere with measurements * subject has a history of sleep apnea * subject has a history of head injury/trauma
oxaliplatin - induced peripheral neuropathy in patients with gastrointestinal tract cancer

Conditions: Gastrointestinal Tract Cancer; Peripheral Neuropathy

Summary: this study will examine dna from gastrointestinal tract of cancer patients treated with oxaliplatin to look for a variation (mutation) of the abcg2 gene that may lead to drug-induced peripheral neuropathy in certain patients. the dna will be extracted from patients' blood samples and are analyzed for the abcg2 single nucleotide polymorphism (g34a - rs2231137 and a/a -rs3114018 genotypes) and correlated with peripheral neuropathy grades.

pharmacogenetic analysis/genotyping : genotyping is conducted via high resolution melting (hrm) technique, to confirm the genotyping results, the polymerase chain reaction (pcr) product of the samples will be examine via direct sequencing using 3500 genetic analyzer from thermofisher (applied biosystem) at two abcg2 loci using the following pcr primers: 1-abcg2 g34a - rs2231137 forward : 5'-tgc aat ctc att tat ctg gac ta-'3 reverse : 5'-aat gcc ttc agg tca ttg ga-'3 -annealing temp :57 -product size : 163 2- abcg2 a/a - rs3114018 forward : 5'- tgatgttccttcagccactg-'3 reverse : 5'-ttgtggaaacctcacaaaagtg-'3 - annealing temp : 59 - product size : 124

Eligibility criteria:
inclusion criteria: * gastrointestinal tract cancer patients treated with oxaliplatin-containing chemotherapy * measurable disease * age of 18 years to 80 years exclusion criteria: * pregnant women * history of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaliplatin. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * neurologic disease or patients with disease impairing the neurologic function affecting
de-nicotinised cigarettes study

Conditions: Smoking Cessation; Tobacco Dependence

Summary: the aim of this study is to determine if using a behavioural replacement for smoking (de-nicotinised cigarettes; dncs), in addition to standard treatment during the first two weeks after the target quit date, can reduce urges to smoke over the first 4-weeks of abstinence. two hundred smokers who want to quit will be recruited from the community. they would all receive standard smoking cessation treatment from the nhs stop smoking service (nhs sss), which uses a combination of stop smoking medication (e.g. nicotine replacement therapy, champix) and motivational support. on their target quit date, participants would be randomised to receive behavioural replacement ( i.e. use of de-nicotinised cigarettes) plus standard treatment for the first two weeks of their quit attempt, or to continue with standard treatment alone. de-nicotinised cigarettes are similar to standard cigarettes except that they do not deliver nicotine to the smoker. participants will rate their urges to smoke at each week. standard nhs sss measures will also be taken in addition to user acceptability ratings and reactions to smoking cues. the hypothesis is that complementing current nhs sss treatments with de-nicotinised cigarettes, to address the non-nicotine factors associated with smoking and to help extinguish smoking behaviour, would result in lower urges to smoke than standard treatment alone.


Eligibility criteria:
inclusion criteria: * 18 years or over * seeking treatment to stop smoking exclusion criteria: * pregnant or breastfeeding * acute psychiatric illness

Keywords: smoking cessation tobacco dependence de-nicotinised cigarettes
effects of anesthesia on atelectasis

Conditions: Atelectasis; General Aneshesia

Summary: we know that respiratory functions of patients are affected under general anaesthesia. although there are many underlying causes of ventilation-perfusion mismatch in the airways, the main cause is atelectasis during general anaesthesia. atelectasis occurs in almost all patients receiving general anaesthesia. the main cause of atelectasis is the loss of muscle tone during general anaesthesia. postoperative atelectasis was described in the last century. it is defined as the closure of the alveoli due to a decrease in inspiratory force and collapse of the lung and the resulting loss of aeration. inhalation anaesthetics have been shown to cause hypoxic pulmonary vasoconstriction in studies. however, not all inhalation anaesthetics affect the airways in the same way. in patients who will undergo surgical procedures under different general anaesthesia maintenance methods, conditions that disrupt the ventilation-perfusion balance in the lung peroperatively can be diagnosed and monitored early, easily and inexpensively by lung ultrasonography. lung ultrasound is a noninvasive, reliable, reliable, radiation-free imaging method that provides instantaneous imaging at the bedside. lung ultrasound score is a scoring system that provides scoring of the loss of ventilation in the lung. for this purpose, it was aimed to divide both lung tissues into 12 areas and to give a score between 0 and 3 points and to show the severity of the loss of aeration according to the resulting total score.


Eligibility criteria:
inclusion criteria: * 18-65 years old asa i-ii surgical procedure time between 2 hours and 5 hours in supine position patients who will undergo rhinoplasty, septorhinoplasty operation patients whose consent was obtained with an informed consent form exclusion criteria: * those with a history of malignant hyperthermia, * people with alcohol or drug addiction, * presence of dementia or confusion, * uncooperative patients, * those with respiratory disease, * those with coronary artery disease, congestive heart failure, * patients with unstable blood pressure, * significant anaemia, liver or kidney disease, * women during pregnancy or lactation, * allergy to anaesthetic agents, * body mass index (bmi) \>30 kg/m2, * those with sepsis or bacterial infection, body temperature below 35°c and above 38°c at control value

Keywords: lung ultrasound score general anesthesia atelectasis inhalation agents
efficacy of two schemes of self-monitoring capillary glucose in gestational diabetes

Conditions: Gestational Diabetes

Summary: gestational diabetes mellitus (gdm) affects 10 % of women who receive prenatal care at instituto nacional de perinatología (mexico, city). currently, there is clear evidence on the utility of self- monitoring of capillary glucose (smgc) to evaluate the efficacy of medical-nutrition therapy on glycemic control. however, the reports regarding the best pattern of smgc in terms of frequency and number of determinations per day are limited. the objective of this study is to evaluate the efficacy of two smgc schemes for monitoring glycemic control in mexican women with gdm.

currently, the evidence from randomized clinical trials about the most appropriate scheme of smgc for monitoring the glycemic control among women with gdm is limited. this study was designed to evaluate the efficacy of two different schemes of smgc in gdm mexican population, it is an open-label randomized clinical trial including 2 groups: group 1 (smgc 4 times/day) measured in fasting and 1 hour postprandial of breakfast, lunch and dinner; group 2 (smgc 2 times/day), measured preprandial and 1 hour postprandial, of breakfast, lunch or dinner, alternating the meal each day, from gdm diagnosis until the resolution of pregnancy. additionally, determinations of insulin, lipids and glycosylated hemoglobin (hba1c) will be determinate at enrollment, and between the 30-32 and 36-38 of gestation week. the primary outcome: to compare the proportion of women who achieve glycemic control using smgc 4 times/day versus smgc 2 times/day. secondary outcome: to compare the risk of new-born large for gestational age, gestational hypertension, preeclampsia, preterm birth, cesarean section, new-born weight, neonatal hypoglycemia, neonatal hyperbilirubinemia and entry to neonatal intensive care between groups. an analysis for intention of treatment will be made according to the recommendations of the consort guidelines.

Eligibility criteria:
inclusion criteria: * gdm diagnosis, defined by 2 or more altered values during oral glucose tolerance test (75g-2h): fasting ≥ 95 mg/dl, 1 hour ≥ 180 mg/dl and 2 hours ≥ 155 mg/dl. * singleton pregnancy between 12-32 weeks of gestation at gdm diagnosis. exclusion criteria: 1. multiple pregnancy. 2. pregestational diabetes. 3. fasting glucose \> 126 mg/dl or random glucose \> 200 mg/dl before 12 weeks of gestation. 4. active pathology: systemic lupus erythematosus, rheumatoid arthritis, congenital or acquired cardiopathy, uterine leiomyoma \> 10cm, renal insufficiency and chronic hypertension.
safety, tolerability and pharmacokinetics of bibw 2948 bs in healthy male volunteers

Conditions: Healthy

Summary: study to investigate safety, tolerability, and pharmacokinetics of bibw 2948 bs


Eligibility criteria:
inclusion criteria: * healthy males based on a complete medical history, including physical examination, vital signs (bp, pr), 12-lead ecg, and clinical laboratory tests: * no finding deviating from normal and of clinical relevance * no evidence of a clinically relevant concomitant disease * aged between ≥21 and ≤50 years * bmi (body mass index) between ≥18.5 and ≤30 kg/m2 * provision of written informed consent signed and dated prior to admission to the study in accordance with good clinical practice (gcp) and local legislation exclusion criteria: * any finding during the medical examination (including bp, pr and ecg) deviating from normal and of clinical relevance * any evidence of a clinically relevant concomitant disease * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * history of relevant orthostatic hypotension, fainting spells or blackouts * chronic or relevant acute infections * history of relevant allergy/hypersensitivity (including allergy to the drug or its excipients) * intake of drugs with a long half-life (\>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial * participation in another trial with an investigational drug within two months prior to administration or during the trial * smoker (\>10 cigarettes or \>3 cigars or \>3 pipes/day) * inability to refrain from smoking on trial days * alcohol abuse (more than 60 g/day) * drug abuse * blood donation (more than 100 ml within four weeks prior to administration or during the trial) * excessive physical activities (within one week prior to administration or during the trial) * any laboratory value outside the reference range that is of clinical relevance * inability to comply with dietary regimen of study centre